Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on antivirals for respiratory viral diseases, alongside legacy oncology assets. The company’s lead influenza candidate, tivoxavir marboxil (TXM), showed prolonged plasma exposure after a single dose and strong preclinical activity against H5N1 bird flu in multiple animal models.
Regulators have affirmed that clinical data are required for bird flu approval, and the U.S. IND for TXM is on clinical hold over toxicology concerns, which the company is working to address. Traws is prioritizing TXM as a once-monthly oral prophylactic for influenza and as a single-dose treatment for seasonal and H5N1 flu.
Ratutrelvir, an oral 3CL protease inhibitor for COVID-19, completed a 90‑patient Phase 2a study versus PAXLOVID, with reports of fewer adverse events, no viral rebound, and comparable symptom resolution. Oncology programs narazaciclib and rigosertib have completed or near-complete early studies and are now primarily positioned for partnering. Research and development expenses were $12.1 million in 2025 and $12.8 million in 2024.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on antivirals for respiratory viral diseases, alongside legacy oncology assets. The company’s lead influenza candidate, tivoxavir marboxil (TXM), showed prolonged plasma exposure after a single dose and strong preclinical activity against H5N1 bird flu in multiple animal models.
Regulators have affirmed that clinical data are required for bird flu approval, and the U.S. IND for TXM is on clinical hold over toxicology concerns, which the company is working to address. Traws is prioritizing TXM as a once-monthly oral prophylactic for influenza and as a single-dose treatment for seasonal and H5N1 flu.
Ratutrelvir, an oral 3CL protease inhibitor for COVID-19, completed a 90‑patient Phase 2a study versus PAXLOVID, with reports of fewer adverse events, no viral rebound, and comparable symptom resolution. Oncology programs narazaciclib and rigosertib have completed or near-complete early studies and are now primarily positioned for partnering. Research and development expenses were $12.1 million in 2025 and $12.8 million in 2024.
Traws Pharma reported 2025 results showing a sharp turnaround to net income of $9.2 million, or $0.83 per basic share, compared with a net loss of $166.5 million in 2024, largely reflecting the absence of prior-year acquired R&D expense and a favorable change in warrant liability.
Revenue rose to $2.8 million from $0.2 million, while R&D and G&A expenses were $12.1 million and $8.5 million, respectively. Cash and cash equivalents were $3.8 million as of December 31 2025. The company completed a private financing of up to $60 million, including $10 million upfront and additional milestone-based warrants, which together with existing cash is expected to fund operations, including a Phase 2a human influenza challenge trial for tivoxavir marboxil, into Q1 2027. Traws also highlighted positive Phase 2a topline data for ratutrelvir in COVID-19.
Traws Pharma reported 2025 results showing a sharp turnaround to net income of $9.2 million, or $0.83 per basic share, compared with a net loss of $166.5 million in 2024, largely reflecting the absence of prior-year acquired R&D expense and a favorable change in warrant liability.
Revenue rose to $2.8 million from $0.2 million, while R&D and G&A expenses were $12.1 million and $8.5 million, respectively. Cash and cash equivalents were $3.8 million as of December 31 2025. The company completed a private financing of up to $60 million, including $10 million upfront and additional milestone-based warrants, which together with existing cash is expected to fund operations, including a Phase 2a human influenza challenge trial for tivoxavir marboxil, into Q1 2027. Traws also highlighted positive Phase 2a topline data for ratutrelvir in COVID-19.
Traws Pharma, Inc. entered into a private investment in public equity financing, raising approximately $10 million in upfront gross proceeds and issuing common stock or pre‑funded warrants plus three series of common stock warrants. The warrants could provide up to an additional $50 million in gross proceeds if fully exercised for cash.
The financing is priced at $1.6730 per share (or $1.6630 per pre‑funded warrant) and is intended to fund a Phase 2a human challenge trial for the company’s influenza program in the United Kingdom. Series A, B and C warrants cover up to 29,914,595 shares in total and are exercisable upon specified regulatory, shareholder and market milestones.
Traws Pharma, Inc. entered into a private investment in public equity financing, raising approximately $10 million in upfront gross proceeds and issuing common stock or pre‑funded warrants plus three series of common stock warrants. The warrants could provide up to an additional $50 million in gross proceeds if fully exercised for cash.
The financing is priced at $1.6730 per share (or $1.6630 per pre‑funded warrant) and is intended to fund a Phase 2a human challenge trial for the company’s influenza program in the United Kingdom. Series A, B and C warrants cover up to 29,914,595 shares in total and are exercisable upon specified regulatory, shareholder and market milestones.
Parker Charles Nolan reported acquisition or exercise transactions in this Form 4 filing.
Traws Pharma, Inc. Chief Financial Officer Parker Charles Nolan reported multiple equity awards from the company. He received 15,393 restricted stock units that vest 100% on the first anniversary of the grant date. He was also granted stock options for 104,544 shares at $1.60, 61,571 shares at $2.33, and 32,406 shares at $3.01 per share, each vesting in full one year after the respective grant dates.
Traws Pharma, Inc. filed an initial ownership report for Chief Financial Officer Parker Charles Nolan on Form 3. The filing lists Nolan as an officer but shows no reportable transactions or holdings in the summarized data, serving as a baseline disclosure of his insider status.
Traws Pharma, Inc. notified the SEC that it cannot timely file its Annual Report on Form 10-K for the period ended December 31, 2025 and is using Rule 12b-25 to seek a 15-calendar-day extension.
The company cites recurring operating losses and ongoing efforts to secure financing to meet Nasdaq Listing Rule 5550(b)(1), and states KPMG LLP will need time to complete audit procedures after management’s going-concern assessment. The notification is signed and dated March 31, 2026.
Traws Pharma director Clarke Trafford received a new stock option grant as part of his compensation. He was awarded options for 33,435 shares of common stock at an exercise price of $1.60 per share. These options were granted under the company’s 2021 Incentive Compensation Plan by the independent compensation committee and will vest 100% on the first anniversary of the March 8, 2026 grant date. Following this award, Trafford holds 33,435 stock options directly, which are scheduled to expire on March 8, 2036.
Traws Pharma, Inc. director Werner Cautreels received a grant of stock options as compensation. He was awarded 31,258 options to buy common stock at an exercise price of $1.6000 per share. These options vest 100% on the first anniversary of the March 8, 2026 grant, and his reported derivative holdings after the grant are 31,258 options.
Traws Pharma director John Harold Leaman received a stock option grant for 33,435 shares of common stock. The options have an exercise price of $1.60 per share and were awarded at no upfront cost as compensation. According to the award terms, the options will vest 100% on the first anniversary of the March 8, 2026 grant date, after which they become exercisable. Following this grant, Leaman holds 33,435 stock options directly.
Traws Pharma, Inc. granted Chief Executive Officer Iain D. Dukes stock options covering 231,336 shares of common stock. The options have a $1.60 exercise price, were awarded at no cost, and will vest 100% on the first anniversary of the March 8, 2026 grant date. They expire on March 8, 2036 and represent compensation approved by the company’s independent compensation committee under its 2021 Incentive Compensation Plan, rather than an open-market share purchase or sale.